Takeda Oncology: Outsmarting Cancer to Transform Lives
Disease Education
Outsmarting Cancer to Profoundly Impact Patients’ Lives
At Takeda Oncology, we aspire to cure cancer with inspiration from patients and innovation from everywhere. We combine rigorous science, innovative commercial operations and the aspiration of transforming cancer from a serious disease to a treatable illness in our efforts to develop transformative medicines. Our demonstrated leadership in the treatment of hematologic cancers and solid tumors combined with cutting-edge science through multiple platforms, partnerships and therapeutic approaches enable us to bring novel medicines to patients worldwide.
Cancer is clever, but we know its weaknesses. We’ve discovered new ways to attack vulnerabilities in cancer that affect specific patient populations with significant unmet need.
Patients with limited or ineffective treatment options motivate us every day. We are committed to outsmarting cancer so that more patients can benefit from – and have access to – life-transforming medicines.
Colorectal Cancer
Colorectal cancer (CRC) is cancer of the large intestine, which is made up of the colon and rectum. These cancers can also be called colon cancer or rectal cancer, depending on where they start.1 CRC is the third most common cancer worldwide, with about 1 in 10 cancer cases and deaths, as of 2020.2
CRC is the second most common cause of cancer-related mortalities.2 By 2030, CRC is expected to increase by 60%, to over 2.2 million new cases and 1.1 million deaths globally.3 With the global incidence of CRC on the rise, treatment advancements in efficacy and tolerability are vital.
Metastatic colorectal cancer can also be referred to as advanced colon cancer or stage 4 colon cancer.4
Lung Cancer
Lung cancer is one of the most common cancers and is the leading cause of cancer death worldwide, as of 2020. Even with substantial improvement in cancer screening, diagnosis, and treatment over the past few decades, lung cancer made up approximately 18% of cancer-related deaths worldwide in 2020.5,6 Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 80-85% of all forms of lung cancer.7
Takeda Oncology’s advanced lung cancer research is focused on expanding treatment options for people with anaplastic lymphoma kinase-positive (ALK+) metastatic NSCLC (mNSCLC). Our ongoing investigation of targeted therapies demonstrates continued progress toward extending and improving the lives of people living with this rare form of NSCLC.
Anaplastic lymphoma kinase-positive (ALK+) NSCLC is a unique type of NSCLC caused by a change in the anaplastic lymphoma kinase (ALK) gene.8
Blood Cancer
Hematologic malignancies, or blood cancers, include leukemia, lymphoma and myeloma. These types of blood cancers can affect the bone marrow, the blood cells, the lymph nodes and other parts of the lymphatic system. In 2022, more than 1.3 million people worldwide were diagnosed with a blood cancer.9
Lymphoma is the most common type of blood cancer.10
Multiple myeloma is a rare blood cancer that arises from the plasma cells, a type of white blood cell which is made in the bone marrow.11
Leukemia is a blood cancer that is characterized by an increase in abnormal blood cells that suppress the development of normal blood and marrow cells.12
References
- American Cancer Society. What is colorectal cancer? Available at: https://www.cancer.org/cancer/colon-rectal-cancer/about/what-is-colorectal-cancer.html. Last accessed January 2023
- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
- Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89-103. doi:10.5114/pg.2018.81072
- Memorial Sloan Kettering Cancer Center. Treatment for Metastatic Colon Cancer. Available at: https://www.mskcc.org/cancer-care/types/colon/treatment/metastases
- World Health Organization. Cancer. 2022. https://www.who.int/news-room/fact-sheets/detail/cancer Accessed February 2023.
- American Cancer Society. Cancer Research Insights from the Latest Decade, 2010 to 2020. Available at: https://www.cancer.org/research/acs-research-news/cancer-research-insights-from-the-latest-decade-2010-to-2020.html.
- American Cancer Society. Key Statistics for Lung Cancer. Available at: https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html
- Gainor JF, Varghese AM, Ou SH, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res. 2013;19(15):4273-81. doi: 10.1158/1078-0432.CCR-13-0318
- World Cancer Research Fund International. Worldwide cancer data. Available at: https://www.wcrf.org/cancer-trends/worldwide-cancer-data/
- Lymphoma Research Foundation. About Lymphoma. Available at: https://lymphoma.org/aboutlymphoma/
- National Cancer Institute. Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version. https://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq#:~:text=Multiple%20myeloma%20cells%20are%20abnormal,increases%2C%20more%20antibodies%20are%20made. Accessed August 2024. Cleveland Clinic. Leukemia. Accessed August. Available at: https://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq#:~:text=Multiple%20myeloma%20cells%20are%20abnormal,increases%2C%20more%20antibodies%20are%20made.
- Cleveland Clinic. Leukemia. Available at: https://my.clevelandclinic.org/health/diseases/4365-leukemia.
